KLK1 is inhibited by several SMIs in the treatment of cardiovascular diseases 53, while the anti-CD14 antibody atibuclimab is administered to patients with amyotrophic lateral sclerosis 54. Here, CD14 is linked to amyotrophic lateral sclerosis.